US Bancorp
BCAX

US Bancorp’s Bicara Therapeutics BCAX Stock Holding History

US Bancorp’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.2K Buy
1,656
+1,405
+560% +$31.4K ﹤0.01% 2808
2026
Q1 		$4.99K Buy
251
+17
+7% +$293 ﹤0.01% 3571
2025
Q4 		$3.94K Sell
234
-1
-0.4% -$17 ﹤0.01% 3615
2025
Q3 		$3.71K Sell
235
-175
-43% -$1.96K ﹤0.01% 3617
2025
Q2 		$3.81K Sell
410
-157
-28% -$1.87K ﹤0.01% 3716
2025
Q1 		$7.39K Buy
+567
New +$7.53K ﹤0.01% 3538

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

US Bancorp's BCAX Position: Q2 2026 in Review

US Bancorp increased its Bicara Therapeutics (BCAX) stake by 560% in Q2 2026, buying an estimated $31.4K and bringing the position to 1,656 shares worth $49.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

US Bancorp first reported a position in BCAX in Q1 2025 and has held it in 6 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • US Bancorp held 1,656 shares of Bicara Therapeutics worth $49.2K as of Q2 2026.
  • US Bancorp bought 1,405 Bicara Therapeutics shares in Q2 2026, an estimated $31.4K.
  • Bicara Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2808 holding.
  • US Bancorp first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.